After MiMedx‘s (MDXG) recent disagreement with the FDA, the company has signed a distribution deal with Medtronic (MDT) for its PURION processed allograft products. Medtronic’s subsidiary SpinalGraft Technologies will promote, market and sell the private-labeled product for spinal applications in the United States.
This comes as happy news for the company, which received an Untitled Letter from the FDA in August.
“This agreement is a significant milestone for MiMedx in expanding our customer base and broadening the breadth of physicians and patients with access to our PURION® processed allografts,” MiMedx CEO and Chairman Parker Petit said in a press release. “By partnering with Medtronic, many additional physicians and patients can be served through the extensive distribution arm and presence that Medtronic has in the spinal surgery market.”
